KMT2D‐mediated H3K4me1 recruits YBX1 to facilitate triple‐negative breast cancer progression through epigenetic activation of c‐Myc.

MLA

Yao, Bing, et al. “KMT2D‐mediated H3K4me1 Recruits YBX1 to Facilitate Triple‐negative Breast Cancer Progression through Epigenetic Activation of C‐Myc.” Clinical & Translational Medicine, vol. 14, no. 7, July 2024, pp. 1–21. EBSCOhost, https://doi.org/10.1002/ctm2.1753.

APA

Yao, B., Xing, M., Zeng, X., Zhang, M., Zheng, Q., Wang, Z., Peng, B., Qu, S., Li, L., Jin, Y., Li, H., Yuan, H., Zhao, Q., & Ma, C. (2024). KMT2D‐mediated H3K4me1 recruits YBX1 to facilitate triple‐negative breast cancer progression through epigenetic activation of c‐Myc. Clinical & Translational Medicine, 14(7), 1–21. https://doi.org/10.1002/ctm2.1753

Chicago

Yao, Bing, Mengying Xing, Xiangwei Zeng, Ming Zhang, Que Zheng, Zhi Wang, Bo Peng, et al. 2024. “KMT2D‐mediated H3K4me1 Recruits YBX1 to Facilitate Triple‐negative Breast Cancer Progression through Epigenetic Activation of C‐Myc.” Clinical & Translational Medicine 14 (7): 1–21. doi:10.1002/ctm2.1753.